Review Note
Last Update: 02/08/2025 09:55 PM
Current Deck: Pharm Cardio Exam 1
Published
Fields:
Front
fosinopril
Back
Class: angiotensin converting enzyme inhibitors (ACE inhibitors)
Subclass: -pril
MOA: inhibits ACE (ace blocks conversion to ANG II); reduces preload and afterload in HTN; decreases left ventricular remodeling caused by chronic HTN and MI
AE: rash; cough (increased bradykinen); hyperkalemia (rare); acute renal failure and elevated serum creatinine; hypotension; angioedema; dysgeusia
Indication: HTN, all pts post MI and HF; diabetic and nondiabetic proteinuria
CI: pregnancy; angioedema; bilateral renal artery stenosis; hyperkalemia; DI: NSAIDs, DIG, lithium levels can be increased (kidneys don't contraindicate)
Route:
Subclass: -pril
MOA: inhibits ACE (ace blocks conversion to ANG II); reduces preload and afterload in HTN; decreases left ventricular remodeling caused by chronic HTN and MI
AE: rash; cough (increased bradykinen); hyperkalemia (rare); acute renal failure and elevated serum creatinine; hypotension; angioedema; dysgeusia
Indication: HTN, all pts post MI and HF; diabetic and nondiabetic proteinuria
CI: pregnancy; angioedema; bilateral renal artery stenosis; hyperkalemia; DI: NSAIDs, DIG, lithium levels can be increased (kidneys don't contraindicate)
Route:
Suggested Changes:
Deck Changes (Suggestion to move the Note to the following Deck):
Field Changes:
Tag Changes: